Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.

Ninčević, Vjera

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. [electronic resource] - International journal of molecular sciences Nov 2019

Publication Type: Journal Article; Review

1422-0067

10.3390/ijms20235831 doi


Animals
Diabetes Mellitus, Type 2--drug therapy
Diabetic Nephropathies--drug therapy
Drug Synergism
Glucagon-Like Peptide-1 Receptor--metabolism
Humans
Hypoglycemic Agents--pharmacology
Kidney--drug effects
Sodium-Glucose Transporter 2--metabolism
Sodium-Glucose Transporter 2 Inhibitors--pharmacology
Glucagon-Like Peptide-1 Receptor Agonists